Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc. (OVID) is a celebrated biopharmaceutical company that singularly focuses on developing transformative drugs for rare neurological disorders. Incorporated in 2014 and headquartered in New York City, OVID is dedicated to addressing the needs of patients and families living with rare neurological disorders that have significant unmet medical needs.

The company’s most advanced therapeutic candidate is OV101 (gaboxadol), which is in advanced clinical development for the treatment of Angelman syndrome and Fragile X syndrome, two severe developmental disorders. OV101 is the first investigational drug to selectively target the disruption of tonically active GABAA channel function, a process believed to play a key role in both conditions.

Secondly, they are developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, for the potential treatment of rare developmental and epileptic encephalopathies. This cellular modifier is designed to reduce seizure susceptibility and improve seizure control, representing a potentially radical advancement in epilepsy management.

These therapies are the foundation of OVID’s strategy to build a leading neurology company focused on rare brain diseases. They employ a targeted development model and work in conjunction with research partners, patients, caregivers and physicians to deliver innovative therapies.

OVID prides itself on its vigorous commitment to research and development, constantly exploring new avenues for therapeutic advancement in neuroscience. The company also deeply values its relationships with patients, their families and caregivers, ensuring their voices are heard, their needs are met, and their lives are improved. The company's mission, “improving the lives of patients and families living with rare neurological disorders,” truly encapsulates their driving force.

OVID's work focuses on disorders that affect cognitive function and significantly limit independence, contributing to the fact that there's a tremendous amount of unmet medical needs to address. Despite the challenges in drug development for these complex brain disorders, OVID remains dedicated to driving scientific discovery and innovation, standing as a beacon of hope to patients and their families navigating these rare, often overlooked neurological conditions.